This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
5 Best Stocks in Nasdaq ETF That Gained in April
by Sweta Killa
The tech-heavy Nasdaq Composite Index logged in the worst month since 2008, having fallen 15%.
DaVita (DVA) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Supply shortage along with pandemic-led incremental mortality rate is likely to have weighed on DaVita's (DVA) first-quarter top line.
The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen
by Zacks Equity Research
Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.
AstraZeneca (AZN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
AstraZeneca's (AZN) first-quarter results reflect a beat on both counts (revenues and earnings). AZN maintains its 2022 guidance.
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
Bristol-Myers (BMY) Q1 Earnings Beat Estimates, Guidance Down
by Zacks Equity Research
Bristol-Myers (BMY) earnings beat estimates in the first quarter of 2022. Sales jump year over year on the back of Eliquis and new products.
Gilead (GILD) Q1 Earnings Beat on Solid COVID Treatment Sales
by Zacks Equity Research
Gilead (GILD) beats on earnings and revenues in the first quarter on strong Veklury sales. HIV business maintains momentum on Biktarvy.
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
by Indrajit Bandyopadhyay
Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) Q1 Earnings and Sales Beat Estimates, Stock Up
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with both sales and earnings beating estimates. RGEN also reduced its financial guidance for 2022
BioMarin (BMRN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Biomarin Pharmaceutical's (BMRN) first-quarter earnings and sales beat estimates. BMRN also raises its financial guidance for 2022 Voxzogo sales by $10 million.
Eli Lilly (LLY) Beats on Q1 Earnings, Ups Sales View, Stock Rises
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for both earnings and sales and ups its sales outlook for 2022. The stock rises in pre-market trading.
Amgen's (AMGN) Q1 Earnings Top, Stock Down on IRS Tax Dispute
by Zacks Equity Research
Amgen (AMGN) beats Q1 estimates for earnings and sales. The stock declines on the announcement of litigation and tax dispute with the IRS.
Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPGP
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) closed at $267.25 in the latest trading session, marking a -0.16% move from the prior day.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Incyte's (INCY) top line is likely to have been driven in the first quarter by the sales of its lead drug, Jakafi.
BD (BDX) Gears Up for Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Interventional segment is expected to have driven up Q2 sales.
Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Chemed's (CHE) Q1 Earnings Top Estimates, Margins Increase
by Zacks Equity Research
In Q1, Chemed's (CHE) VITAS revenue decline was primarily the result of a 4.1% decline in days of care.
Ecolab's (ECL) Q1 Earnings in Line, Revenues Beat Estimates
by Zacks Equity Research
Ecolab's (ECL) robust performance across all of its segments drives its Q1 sales despite business challenges.
Quidel (QDEL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Quidel's (QDEL) first-quarter results are likely to reflect continued strength across its SARS-related products.
Novartis (NVS) Beats on Q1 Earnings, Sandoz Posts Growth
by Zacks Equity Research
Novartis (NVS) beats on earnings in the first quarter but sales lag expectations. Generic Sandoz business returns to growth.
Is a Beat Likely for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
AbbVie's (ABBV) first-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to focus on any update related to Humira LOE.
Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug
by Zacks Equity Research
The CHMP gives a positive opinion on, and recommends approval for Novartis' (NVS) Tabrecta for treating patients with METex14 advanced non-small cell lung cancer.
Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs
by Zacks Equity Research
Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.